Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Igreja

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Journal of the American Society of Hypertension : JASH|January 25, 2016
Sustained high blood pressure reduction with etamicastat, a peripheral selective dopamine β-hydroxylase inhibitorBruno Igreja, Lyndon C Wright, Patricio Soares-da-Silva
Clinical and Experimental Hypertension (New York, N.Y. : 1993)|March 10, 2021
Antagonistic modulation of SIK1 and SIK2 isoforms in high blood pressure and cardiac hypertrophy triggered by high-salt intakeNuno M Pires, Bruno Igreja, Patrício Soares-da-Silva
European Journal of Pharmacology|November 8, 2018
Effects of zamicastat treatment in a genetic model of salt-sensitive hypertension and heart failureBruno Igreja, Nuno M Pires, Lyndon C Wright, et al.
ACS Pharmacology & Translational Science|April 8, 2020
Cardiometabolic and Inflammatory Benefits of Sympathetic Down-Regulation with Zamicastat in Aged Spontaneously Hypertensive RatsBruno Igreja, Nuno Pires, Ana Loureiro, et al.
European Journal of Pharmacology|February 3, 2015
Cardiovascular safety pharmacology profile of etamicastat, a novel peripheral selective dopamine-β-hydroxylase inhibitorNuno Miguel Pires, Ana Isabel Loureiro, Bruno Igreja, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|April 10, 2015
Blood pressure decrease in spontaneously hypertensive rats folowing renal denervation or dopamine β-hydroxylase inhibition with etamicastatNuno Miguel Pires, Bruno Igreja, Eduardo Moura, et al.
European Journal of Pharmacology|July 25, 2014
Etamicastat, a new dopamine-ß-hydroxylase inhibitor, pharmacodynamics and metabolism in ratAna I Loureiro, Maria João Bonifácio, Carlos Fernandes-Lopes, et al.
European Journal of Pharmacology|May 14, 2021
The role of salt-inducible kinases on the modulation of renal and intestinal Na<sup>+</sup>,K<sup>+</sup>-ATPase activity during short- and long-term high-salt intakeTatiana António, Dina Cosme, Bruno Igreja, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|April 28, 2015
Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastatAna I Loureiro, Maria João Bonifácio, Carlos Fernandes-Lopes, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|October 10, 2014
Blood pressure-decreasing effect of etamicastat alone and in combination with antihypertensive drugs in the spontaneously hypertensive ratBruno Igreja, Nuno Miguel Pires, Maria João Bonifácio, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Journal of the American Society of Hypertension : JASH|January 25, 2016
Sustained high blood pressure reduction with etamicastat, a peripheral selective dopamine β-hydroxylase inhibitorBruno Igreja, Lyndon C Wright, Patricio Soares-da-Silva
Clinical and Experimental Hypertension (New York, N.Y. : 1993)|March 10, 2021
Antagonistic modulation of SIK1 and SIK2 isoforms in high blood pressure and cardiac hypertrophy triggered by high-salt intakeNuno M Pires, Bruno Igreja, Patrício Soares-da-Silva
European Journal of Pharmacology|November 8, 2018
Effects of zamicastat treatment in a genetic model of salt-sensitive hypertension and heart failureBruno Igreja, Nuno M Pires, Lyndon C Wright, et al.
ACS Pharmacology & Translational Science|April 8, 2020
Cardiometabolic and Inflammatory Benefits of Sympathetic Down-Regulation with Zamicastat in Aged Spontaneously Hypertensive RatsBruno Igreja, Nuno Pires, Ana Loureiro, et al.
European Journal of Pharmacology|February 3, 2015
Cardiovascular safety pharmacology profile of etamicastat, a novel peripheral selective dopamine-β-hydroxylase inhibitorNuno Miguel Pires, Ana Isabel Loureiro, Bruno Igreja, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|April 10, 2015
Blood pressure decrease in spontaneously hypertensive rats folowing renal denervation or dopamine β-hydroxylase inhibition with etamicastatNuno Miguel Pires, Bruno Igreja, Eduardo Moura, et al.
European Journal of Pharmacology|July 25, 2014
Etamicastat, a new dopamine-ß-hydroxylase inhibitor, pharmacodynamics and metabolism in ratAna I Loureiro, Maria João Bonifácio, Carlos Fernandes-Lopes, et al.
European Journal of Pharmacology|May 14, 2021
The role of salt-inducible kinases on the modulation of renal and intestinal Na<sup>+</sup>,K<sup>+</sup>-ATPase activity during short- and long-term high-salt intakeTatiana António, Dina Cosme, Bruno Igreja, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|April 28, 2015
Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastatAna I Loureiro, Maria João Bonifácio, Carlos Fernandes-Lopes, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|October 10, 2014
Blood pressure-decreasing effect of etamicastat alone and in combination with antihypertensive drugs in the spontaneously hypertensive ratBruno Igreja, Nuno Miguel Pires, Maria João Bonifácio, et al.
Pageof 2